K2M Group Holdings, Inc. (KTWO) CFO Gregory S. Cole Sells 42,947 Shares of Stock

K2M Group Holdings, Inc. (NASDAQ:KTWO) CFO Gregory S. Cole sold 42,947 shares of K2M Group Holdings stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $22.80, for a total transaction of $979,191.60. Following the completion of the transaction, the chief financial officer now directly owns 87,425 shares of the company’s stock, valued at $1,993,290. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

K2M Group Holdings, Inc. (NASDAQ KTWO) traded up 3.17% on Monday, reaching $23.42. 275,834 shares of the company’s stock were exchanged. K2M Group Holdings, Inc. has a 12 month low of $14.49 and a 12 month high of $23.92. The firm has a 50-day moving average of $22.41 and a 200-day moving average of $20.99. The firm’s market capitalization is $996.66 million.

K2M Group Holdings (NASDAQ:KTWO) last released its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.02. K2M Group Holdings had a negative return on equity of 16.02% and a negative net margin of 17.48%. The firm had revenue of $61.89 million for the quarter, compared to the consensus estimate of $60.10 million. On average, equities analysts expect that K2M Group Holdings, Inc. will post ($0.80) earnings per share for the current year.

Insider Buying and Selling by Quarter for K2M Group Holdings (NASDAQ:KTWO)

TRADEMARK VIOLATION NOTICE: “K2M Group Holdings, Inc. (KTWO) CFO Gregory S. Cole Sells 42,947 Shares of Stock” was first posted by BBNS and is owned by of BBNS. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://baseballnewssource.com/markets/k2m-group-holdings-inc-ktwo-cfo-gregory-s-cole-sells-42947-shares-of-stock/1043686.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. TimesSquare Capital Management LLC raised its position in K2M Group Holdings by 44.0% in the first quarter. TimesSquare Capital Management LLC now owns 2,197,020 shares of the medical device company’s stock valued at $45,061,000 after buying an additional 671,120 shares during the last quarter. Citadel Advisors LLC raised its position in K2M Group Holdings by 3,357.5% in the first quarter. Citadel Advisors LLC now owns 628,808 shares of the medical device company’s stock valued at $12,897,000 after buying an additional 610,621 shares during the last quarter. JPMorgan Chase & Co. raised its position in K2M Group Holdings by 54.3% in the first quarter. JPMorgan Chase & Co. now owns 1,409,360 shares of the medical device company’s stock valued at $28,906,000 after buying an additional 495,749 shares during the last quarter. Next Century Growth Investors LLC raised its position in K2M Group Holdings by 134.8% in the first quarter. Next Century Growth Investors LLC now owns 553,654 shares of the medical device company’s stock valued at $11,355,000 after buying an additional 317,878 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its position in K2M Group Holdings by 114.0% in the first quarter. Point72 Asset Management L.P. now owns 555,500 shares of the medical device company’s stock valued at $11,393,000 after buying an additional 295,900 shares during the last quarter. 98.82% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently commented on KTWO shares. Royal Bank Of Canada reaffirmed a “buy” rating on shares of K2M Group Holdings in a report on Wednesday, May 3rd. Zacks Investment Research raised shares of K2M Group Holdings from a “sell” rating to a “hold” rating in a research note on Thursday, March 23rd. Barclays PLC boosted their target price on shares of K2M Group Holdings from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, April 24th. Oppenheimer Holdings, Inc. set a $26.00 target price on shares of K2M Group Holdings and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Finally, Cowen and Company reissued an “outperform” rating and set a $26.00 target price (up from $21.00) on shares of K2M Group Holdings in a research note on Sunday, April 9th. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $25.13.

About K2M Group Holdings

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Hitters in Major League Baseball on Record Home Run Pace
Hitters in Major League Baseball on Record Home Run Pace
Atlanta Considering Playing Freddie Freeman at Third
Atlanta Considering Playing Freddie Freeman at Third
Injury to Gleyber Torres Adds to Questions About Yankees
Injury to Gleyber Torres Adds to Questions About Yankees
Game Winning Home Run Completes Nolan Arenado Cycle
Game Winning Home Run Completes Nolan Arenado Cycle
New York Yankees and Masahiro Tanaka Hit Hard Again
New York Yankees and Masahiro Tanaka Hit Hard Again
Victor Martinez Diagnosed with Irregular Heartbeat
Victor Martinez Diagnosed with Irregular Heartbeat


Leave a Reply

 
© 2006-2017 BBNS.